Treace Medical Concepts, Inc.
TMCI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $50 | $47 | $53 | $69 |
| % Growth | 6% | -9.9% | -23.5% | – |
| Cost of Goods Sold | $11 | $10 | $11 | $13 |
| Gross Profit | $40 | $38 | $42 | $55 |
| % Margin | 79.1% | 79.7% | 79.7% | 80.7% |
| R&D Expenses | $5 | $5 | $6 | $5 |
| G&A Expenses | $16 | $16 | $16 | $14 |
| SG&A Expenses | $50 | $49 | $52 | $50 |
| Sales & Mktg Exp. | $33 | $33 | $36 | $37 |
| Other Operating Expenses | $1 | $0 | $0 | $0 |
| Operating Expenses | $55 | $55 | $57 | $56 |
| Operating Income | -$16 | -$17 | -$16 | -$0 |
| % Margin | -31.2% | -35.8% | -29.6% | -0.3% |
| Other Income/Exp. Net | -$1 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$16 | -$17 | -$16 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$16 | -$17 | -$16 | -$1 |
| % Margin | -32.4% | -36.7% | -30.3% | -0.7% |
| EPS | -0.26 | -0.28 | -0.25 | -0.008 |
| % Growth | 7.1% | -12% | -3,025% | – |
| EPS Diluted | -0.26 | -0.28 | -0.25 | -0.008 |
| Weighted Avg Shares Out | 64 | 63 | 63 | 62 |
| Weighted Avg Shares Out Dil | 64 | 63 | 63 | 62 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $1 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $3 | $3 | $2 | $2 |
| EBITDA | -$12 | -$14 | -$12 | $3 |
| % Margin | -24.2% | -28.5% | -23.1% | 4.4% |